Open AccessCD4 + T Cell‐Released Extracellular Vesicles Potentiate the Efficacy of the HBsAg Vaccine by Enhancing B Cell Responses
Author(s) -
Lu Jian,
Wu Jing,
Xie Feiting,
Tian Jie,
Tang Xinyi,
Guo Hongye,
Ma Jie,
Xu Ping,
Mao Lingxiang,
Xu Huaxi,
Wang Shengjun
Publication year - 2019
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201802219
Subject(s) - immune system , cd40 , antigen , t cell , hbsag , b cell , immunology , cell , antibody , biology , naive b cell , microbiology and biotechnology , antigen presenting cell , chemistry , in vitro , cytotoxic t cell , hepatitis b virus , biochemistry , virus
T cells secrete bioactive extracellular vesicles (EVs), but the potential biological effects of CD4 + T cell EVs are not clear. The main purpose of this study is to investigate the effects of CD4 + T cell–derived EVs on B cell responses and examine their role in antigen‐mediated humoral immune responses. In this study, CD4 + T cell EVs are purified from activated CD4 + T cells in vitro. After immunization with the Hepatitis B surface antigen (HBsAg) vaccine, CD4 + T cell EVs‐treated mice show stronger humoral immune responses, which is indicated by a greater Hepatitis B surface antibody (HBsAb) level in serum and a greater proportion of plasma cells in bone marrow. In addition, it is found that EVs released from activated CD4 + T cells play an important role in B cell responses in vitro, which significantly promote B cell activation, proliferation, and antibody production. Interestingly, antigen‐specific CD4 + T cell EVs are found to be more efficient than control EVs in enhancing B cell responses. Furthermore, it is shown that CD40 ligand (CD40L) is involved in CD4 + T cell EVs‐mediated B cell responses. Overall, the results have demonstrated that CD4 + T cell EVs enhance B cell responses and serve as a novel immunomodulator to promote antigen‐specific humoral immune responses.